How common are ALS plateaus and reversals?

Richard S Bedlack, Timothy Vaughan, Paul Wicks, Jamie Heywood, Ervin Sinani, Roger Selsov, Eric A Macklin, David Schoenfeld, Merit Cudkowicz, Alex Sherman, Richard S Bedlack, Timothy Vaughan, Paul Wicks, Jamie Heywood, Ervin Sinani, Roger Selsov, Eric A Macklin, David Schoenfeld, Merit Cudkowicz, Alex Sherman

Abstract

Objective: To determine the frequency of amyotrophic lateral sclerosis (ALS) plateaus and reversals in the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.

Methods: We analyzed Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) and ALSFRS-revised (ALSFRS-R) data from PRO-ACT participants. The frequencies of participants experiencing plateaus (periods where scores did not change) were calculated over 6-, 12-, and 18-month epochs. The percentage of participants ever experiencing reversals (periods where scores improved) of different lengths were also calculated and plotted.

Results: Over 6 months, 25% of 3,132 participants did not decline. Over 12 months, 16% of 2,105 participants did not decline. Over 18 months, 7% of 1,218 participants did not decline. Small ALS reversals were also common, especially over shorter follow-up intervals; 14% of 1,343 participants had a 180-day interval where their ALSFRS-R slope was greater than zero. Fewer than 1% of participants ever experienced improvements of 4 or more ALSFRS-R points lasting at least 12 months.

Conclusion: ALS plateaus and small reversals are common, especially over brief intervals. In light of these data, stable disease, especially for a short period of time, should not be interpreted as an ALS treatment effect. Large sustained ALS reversals, on the other hand, are rare, potentially important, and warrant further study.

© 2015 American Academy of Neurology.

Figures

Figure 1. Natural history of amyotrophic lateral…
Figure 1. Natural history of amyotrophic lateral sclerosis progression in PRO-ACT
These histograms show the natural history of Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) participants' Amyotrophic Lateral Sclerosis Functional Rating Score (ALSFRS) changes at intervals of 6 months (A), 12 months (B), and 18 months (C).
Figure 2. Closer look at amyotrophic lateral…
Figure 2. Closer look at amyotrophic lateral sclerosis reversals
These graphs show 2 individual Pooled Resource Open-Access ALS Clinical Trials participants' Amyotrophic Lateral Sclerosis Functional Rating Score–revised (ALSFRS-R) scores over time. The portion of the curve picked up as an amyotrophic lateral sclerosis reversal is highlighted. Some of these reversals appear to be the result of a single data point (participant A, last data point). Others include multiple incrementally improving data points, which are potentially more interesting (participant B).

References

    1. Tucker T, Layzer R, Miller R, Chad D. Subacute reversible motor neuron disease. Neurology 1991;41:1541–1544.
    1. Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) (NIPALS2013). Available at: . Accessed May 6, 2015.
    1. Atassi N, Berry J, Shui A, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology 2014;83:1719–1725.
    1. Cedarbaum J, Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci 1997;152:S1–S9.
    1. Cedarbaum J, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 1999;169:13–21.
    1. Tzartos J, Zisimopoulou P, Rentzos M, et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol 2014;1:80–87.
    1. Van Hoecke A, Schoonaert L, Lemmens R, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 2012;18:1418–1422.
    1. Samson M, Libert F, Doranz B, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722–725.
    1. Chio A, Canosa A, Gallo S, et al. ALS clinical trials: do enrolled patients accurately represent the ALS population? Neurology 2011;77:1432–1437.
    1. Methods appraisal in psychiatry. Available at: . Accessed August 12, 2015.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever